Glen Berger, MD
Internal Medicine · Ho Ho Kus, NJNPI 1285697201
Payments from drug & device makers
Across 347 payments — averaging $40.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$5K
- Amgen$2K
- Biohaven Pharmaceuticals, Inc.$1K
- GSK$1K
- Johnson & Johnson$1K
- Novo Nordisk$686
- plus $2K from 22 others
What the payments were for
- Consulting fees$2,00014%
- Speaking & faculty fees$1,50011%
- Travel & lodging$8946%
- Food & beverage$9,56268%
- Education$250%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 87 | $5,112 |
| Amgen | 83 | $2,280 |
| Biohaven Pharmaceuticals, Inc. | 6 | $1,476 |
| GSK | 23 | $1,177 |
| Johnson & Johnson | 16 | $1,009 |
| Novo Nordisk | 25 | $686 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $315 |
| Currax Pharmaceuticals LLC | 20 | $307 |
| Novartis | 13 | $277 |
| Exact Sciences | 5 | $216 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $139 |
| Pfizer | 9 | $136 |
| Kowa Pharmaceuticals America, Inc. | 10 | $136 |
| Boston Scientific | 1 | $124 |
| AstraZeneca | 8 | $112 |
| Lilly USA, LLC | 5 | $77 |
| Arbor Pharmaceuticals, Inc. | 5 | $68 |
| Abbott | 3 | $63 |
| Teva Pharmaceuticals USA, Inc. | 4 | $53 |
| Irhythm Technologies, Inc. | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $33 |
| Esperion Therapeutics, Inc. | 2 | $32 |
| Bausch Health US, LLC | 1 | $28 |
| Boehringer Ingelheim | 2 | $24 |
| Axsome Therapeutics, Inc. | 1 | $23 |
| Vivus LLC | 1 | $18 |
| Medicure Pharma Inc. | 1 | $14 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$3,376
- NURTEC ODT$1,692
- XARELTO$995
- Repatha$853
- VRAYLAR$834
- TRELEGY ELLIPTA$371
- EVENITY$354
- ANORO$347
- Wegovy$125
- Ozempic$124
- Watchman$124
- Saxenda$122
- The Cologuard Plus Collection Kit$107
- TRULANCE$105
How this compares
$13,981 in reported general payments places this provider in the 95th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 45 | $44,052 |
| MounjaroTirzepatide | 37 | $42,409 |
| JardianceEmpagliflozin | 40 | $41,505 |
| OzempicSemaglutide | 26 | $38,813 |
| EliquisApixaban | 26 | $31,291 |
| XareltoRivaroxaban | 23 | $15,825 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $8,309 |
| Rosuvastatin Calcium | 262 | $4,352 |
| Valsartan | 122 | $3,735 |
| Atorvastatin Calcium | 283 | $3,633 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $2,535 |
| Levothyroxine Sodium | 141 | $1,778 |
| Metoprolol Succinate | 104 | $1,752 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 26 | $1,533 |
| Amlodipine Besylate | 188 | $1,396 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia | $13 | $44,05245 claims |
| Lilly USA, LLCMounjaro | $77 | $42,40937 claims |
| Boehringer IngelheimJardiance | $24 | $41,50540 claims |
| Novo NordiskOzempic | $686 | $38,81326 claims |
| PfizerEliquis | $136 | $31,29126 claims |
| Johnson & JohnsonXarelto | $1,009 | $15,82523 claims |
| GSKTrelegy Ellipta | $1,177 | $8,30913 claims |
| AbbVieSynthroid | $5,112 | $1,19327 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in Ho Ho Kus
- Sanjiv SharmaToms River$33.9M
- Jeffrey CarsonNew Brunswick$13.8M
- Samer HaddadHamilton$6.8M
- Magdy ShenoudaWall$3.7M
- Samar HameedLivingston$3.6M
- Jane RohlfTrenton$2.7M
- Mohammed NisarEdison$2.6M
- Michael CasserNew Milford$2.2M
- Sumitha ReddyHamilton$2M
- Helio PedroNewark$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.